Idenix Pharmaceuticals, Inc. (IDIX) Reports Q3 Loss of 12c
Tweet
Share
E-mailGet Alerts IDIX Hot Sheet
Join SI Premium – FREE
Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) reported Q3 EPS of ($0.12), $0.03 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $2.64 million versus the consensus estimate of $2.56 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Wolfspeed (WOLF) Misses Q4 EPS by 174c; Offers Guidance
- ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
